Ipsen, a global biopharmaceutical group, announced it will establish its North American headquarters in Cambridge, Massachusetts. The announcement was made at the 2018 BIO International Convention in Boston with the Massachusetts Life Sciences Center (MLSC), an economic development investment agency dedicated to supporting the growth and development of the life sciences in Massachusetts.
Ipsen will create its third global headquarters by consolidating its U.S. business in Cambridge, the leading global biotech hub. Ipsen will co-locate its North America business with its Global External Innovation and Partnering, R&D and Manufacturing teams, as well as certain global Commercial roles, creating a fully integrated biopharmaceutical business in the US.
“We are entering into a new era of innovation and growth for Ipsen as a leading global biotech company. By bringing our headquarters to Cambridge, we will build a sustainable innovation engine to advance opportunities for our employees and our overall business,” said Richard Paulson, CEO of Ipsen North America. “The MLSC has been instrumental throughout this process, and we look forward to continuing to partner with them as we grow our footprint even further in Cambridge and ultimately address patient needs.”
Ipsen will capitalize on Cambridge’s biotech ecosystem to support its accelerated growth, raise its profile and visibility as an employer and partner of choice. Ipsen already has an established presence in Cambridge with two sites in Kendall Square: a manufacturing site located in One Kendall Square and the 650 East Kendall Street offices, which houses its Global External Innovation and Partnering, and Research & Development activities.
“Our administration is committed to supporting strategic investments in life sciences, research, and development and is pleased that Ipsen has chosen to expand its footprint by relocating its headquarters to here in the Commonwealth,” said Massachusetts Governor Charlie Baker. “Massachusetts continues to be a global leader in the life sciences industry and we welcome Ipsen’s planned growth in employment and investment that will spur continued innovation, collaboration and economic growth.”
Ipsen’s U.S. headquarters, currently based in Basking Ridge, NJ, will transition to Cambridge over the next 12 months. Ipsen’s two additional global biotech hubs will remain in the United Kingdom and France. The organization will also maintain a core services center in Basking Ridge, NJ.